Mohammed Milhem: UIHC Helped the First Drug for Metastatic UM to Get FDA Approval
Mohammed Milhem/University of Iowa Health Care

Mohammed Milhem: UIHC Helped the First Drug for Metastatic UM to Get FDA Approval

Mohammed Milhem, Professor of Internal Medicine, Division of Hematology and Oncology; Sarcoma and Melanoma Specialist at University of Iowa Health Care, shared on LinkedIn:

“Iowa played a substantial role in helping this agent get FDA approval as the first drug for the treatment of metastatic uveal melanoma.”

Learn More

You can also read:

CHOPIN Trial: Percutaneous Hepatic Perfusion Plus Ipilimumab and Nivolumab in Metastatic Uveal Melanoma

Mohammed Milhem: UIHC Helped the First Drug for Metastatic UM to Get FDA Approval